SCHEMBL5961823

SCHEMBL5961823

C=CC(=O)OCOc1ccc(OCOc2ccc3c(c2)C(C)c2cc(OC(=O)c4ccc(OCOC(=O)C=C)cc4)ccc2-3)cc1

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.35
MAPT P10636 6/20 0.35
THRB P10828 2/20 0.34
MEN1 O00255 2/20 0.34
CCNC P24863 1/20 0.33
CDK8 P49336 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GBA1 P04062 2/20 0.32
HSD17B10 Q99714 1/20 0.32
PDGFRB P09619 1/20 0.32
PDGFRA P16234 1/20 0.32
PRSS1 P07477 1/20 0.32
ACR P10323 1/20 0.32
HIF1A Q16665 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11986163 0.98 KMT2A (0.36) KMT2AMAPTTHRBMEN1CCNC
SCHEMBL16660342 0.94 GBA1 (0.40) KMT2AMAPTGBA1PDGFRBPDGFRA
SCHEMBL15480714 0.93 THRB (0.45) KMT2AMAPTTHRBMEN1TDP1
SCHEMBL13289441 0.93 KMT2A (0.37) KMT2AMAPTTHRBMEN1TDP1
SCHEMBL19759250 0.91 MAPT (0.35) KMT2AMAPTTHRBMEN1TDP1
SCHEMBL13226628 0.90 HIF1A (0.34) KMT2AMAPTTHRBMEN1TDP1
SCHEMBL11986078 0.90 MAPT (0.35) KMT2AMAPTTHRBMEN1TDP1
SCHEMBL5961822 0.89 KMT2A (0.34) KMT2AMAPTTHRBMEN1CCNC
SCHEMBL18200237 0.88 THRB (0.43) KMT2AMAPTTHRBTDP1L3MBTL1
SCHEMBL14588420 0.88 THRB (0.43) KMT2AMAPTTHRBTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168734-B2 Lateral alpha-substituted acrylate compound and polymer thereof JNC CORPORATION (JP) 2012-05-01 US disclosed
US-20110144293-A1 LATERAL ALPHA-SUBSTITUTED ACRYLATE COMPOUND AND POLYMER THEREOF CHISSO CORPORATION (JP) 2011-06-16 US disclosed
US-7919648-B2 Lateral α-substituted acrylate compound and polymer thereof CHISSO CORPORATION (JP) 2011-04-05 US disclosed
US-7597945-B2 Optical compensation film; mixture of three (meth)acrylate monomers: e.g. 2,7-bis(acryloyloxyhexyloxy-1,4-phenylenecarbonyloxy)fluorene, a bis 2-fluoroacrylate monomer, and a cyanobiphenyloxyalkanol ester of (meth)acrylic acid; hardness, heat resistance, weatherability, colorless, LC physical properties CHISSO CORPORATION (JP) 2009-10-06 US disclosed
US-7488519-B2 Polymerizable liquid crystal composition CHISSO CORPORATION (JP) 2009-02-10 US disclosed
US-20080241431-A1 Polymerizable liquid crystal composition CHISSO CORPORATION 2008-10-02 US disclosed
US-7413782-B2 Polymerizing binaphthalene derivatives CHISSO CORPORATION (JP) 2008-08-19 US disclosed
US-7410677-B2 Organosilicon compound-containing polymerizable liquid-crystal composition CHISSO CORPORATION (JP) 2008-08-12 US disclosed
US-20070134447-A1 Lateral a-substituted acrylate compound and polymer thereof CHISSO CORPORATION 2007-06-14 US disclosed
US-7157124-B2 Polymerizable compounds and their polymers CHISSO PETROCHEMICAL CORPORATION (JP) 2007-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144293-A1 LATERAL ALPHA-SUBSTITUTED ACRYLATE COMPOUND AND POLYMER THEREOF LEF1, AFF1, CNKSR1 KMT2A 1856/4885MAPT 3921/4885THRB 1814/4885
US-20070134447-A1 Lateral a-substituted acrylate compound and polymer thereof AFF1, CNKSR1, LEF1 KMT2A 922/4885MAPT 3961/4885THRB 3134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.